162 related articles for article (PubMed ID: 37621688)
41. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.
Tremblay G; Majethia U; Breeze JL; Kontoudis I; Park J
Clinicoecon Outcomes Res; 2016; 8():485-493. PubMed ID: 27698565
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective.
Zhu W; Zheng M; Xia P; Hong W; Ma G; Shen A
Front Oncol; 2023; 13():1068463. PubMed ID: 36998437
[TBL] [Abstract][Full Text] [Related]
43. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Shi D; Li Y; Liang X; Chen L
Front Oncol; 2023; 13():1162360. PubMed ID: 37251935
[TBL] [Abstract][Full Text] [Related]
45. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.
Li JB; Lin ZC; Wong MCS; Wang HHX; Li M; Li S
BMC Med; 2022 Sep; 20(1):320. PubMed ID: 36156186
[TBL] [Abstract][Full Text] [Related]
46. Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.
Machado M; Einarson TR
Breast Cancer (Dove Med Press); 2012; 4():173-82. PubMed ID: 24367204
[TBL] [Abstract][Full Text] [Related]
47. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
[TBL] [Abstract][Full Text] [Related]
48. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.
Zeng W; Cao X; Lin J; Zheng B; Li N; Liu M; Cai H
Front Oncol; 2023; 13():1272586. PubMed ID: 38169749
[TBL] [Abstract][Full Text] [Related]
50. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Geyer CE; Forster J; Lindquist D; Chan S; Romieu CG; Pienkowski T; Jagiello-Gruszfeld A; Crown J; Chan A; Kaufman B; Skarlos D; Campone M; Davidson N; Berger M; Oliva C; Rubin SD; Stein S; Cameron D
N Engl J Med; 2006 Dec; 355(26):2733-43. PubMed ID: 17192538
[TBL] [Abstract][Full Text] [Related]
51. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
52. Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.
Delea TE; Amdahl J; Chit A; Amonkar MM
Curr Oncol; 2013 Oct; 20(5):e371-87. PubMed ID: 24155635
[TBL] [Abstract][Full Text] [Related]
53. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
[TBL] [Abstract][Full Text] [Related]
54. Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis.
Feng M; Yang Y; Liao W; Li Q
Clin Breast Cancer; 2022 Jul; 22(5):e629-e635. PubMed ID: 35418312
[TBL] [Abstract][Full Text] [Related]
55. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Le QA; Hay JW
Cancer; 2009 Feb; 115(3):489-98. PubMed ID: 19117341
[TBL] [Abstract][Full Text] [Related]
57. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
[TBL] [Abstract][Full Text] [Related]
58. Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib.
Le QA
Med Decis Making; 2016 Jul; 36(5):629-40. PubMed ID: 26753626
[TBL] [Abstract][Full Text] [Related]
59. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
60. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
